Flore Evidence Brief for Health Writers
For health writers and editors. This page lists what Flore has measured, how each number was counted, and where each one stops. Quote any figure here with its label. If you need something we don't list, ask us. We'd rather say "we don't know" than give you a number we can't back.
Who Flore is
Flore makes personalized probiotic and prebiotic formulas, delivered as capsules or powder. Each formula is built from a person's own gut microbiome data: up to 68 curated strains plus 40+ prebiotics. Flore was founded in 2018 and acquired Sun Genomics in 2026. Flore does not run lab tests itself. CLIA-certified, CAP-accredited partner labs sequence the samples, and Flore builds the formula from the results.
The numbers, with what each one counts
| Figure | What it counts | Limits |
|---|---|---|
| 18,700+ customers | Distinct people served, Flore and Sun Genomics combined, as of October 2026. | A floor, not an exact count. Staff and test accounts are excluded. |
| 23,000+ microbiome reports analyzed | Gut microbiome reports Flore has analyzed. | Higher than the customer count because people re-test. Partner labs did the sequencing, not Flore. |
| 40,000+ personalized formulations | Distinct formulas Flore has built. | One person can have several formulas over time. It is not one formula per customer. |
| 10 years of data | Paired microbiome and outcome data, most of it gathered by Sun Genomics before the 2026 acquisition. | Real-world data. Not collected under a trial protocol. |
| 651 paired subjects | People who reported 1,379 baseline symptoms and were followed to a first follow-up. | Observational and self-reported. No control group. We do not publish a resolution rate from this cohort. |
| 95.1% kept their first formula | Of 18,392 pre-2026 customers, the share who did not file a complaint asking for a reformulation. | A tolerability and fit measure. It does not measure symptom improvement. |
The peer-reviewed study, and what it is not
Sun Genomics, the company Flore acquired in 2026, published a study in mSystems (American Society for Microbiology) in 2024: "Precision synbiotics increase gut microbiome diversity and improve gastrointestinal symptoms in a pilot open-label study for autism spectrum disorder" (Phan et al., doi:10.1128/msystems.00503-24, PMID 38661344).
- Design: a pilot, open-label study. 296 children and adults with ASD enrolled and 170 completed 3 months of personalized synbiotics. 123 age-matched neurotypical people gave baseline samples for comparison.
- It is not a randomized controlled trial. Everyone in the ASD group got the synbiotic. There was no placebo arm and no blinding. The authors note the open-label design may include some placebo effects.
- What it found: after supplementation, the ASD group showed higher gut microbiome (alpha) diversity and a significant reduction in GI discomfort.
- What we don't claim from it: any effect on autism itself, behavior, language or cognition.
- Conflict of interest: most authors were Sun Genomics employees. The paper's conflict-of-interest statement says so.
How to describe Flore accurately
- Flore is a personalized probiotic, not a diagnostic test company and not a drug. Its formulas are dietary supplements.
- Say "reports analyzed," not "tests sequenced." Accredited partner labs sequence; Flore analyzes and formulates.
- Flore is spelled without an accent. Flore Inc. acquired Sun Genomics in 2026, so older coverage may credit Sun Genomics. Use "Flore" today.
- Product form is capsules or powder, never a liquid.
- For readers who want the full picture of our real-world data, see The Evidence Behind Flore.
Press contact
Flore Inc. · 51 W. Jackson St, Ste 105, Joliet, IL 60432 · +1 415-326-4743 · [email protected] (subject line "Press inquiry"). We can set up interviews with our CEO, Craig Rouskey, and data briefings on any figure above.
These statements have not been evaluated by the Food and Drug Administration. Flore products are not intended to diagnose, treat, cure, or prevent any disease.